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CorticosteroidsAbstract Background: Drug utilization plays a role in helping the health care system to under-
stand, interpret and improve the drug use and continuous quality improvement. It plays an essential
part of pharmaco-epidemiological studies. The purpose of this study was to evaluate the drug
utilization trends in patients with acute exacerbation of bronchial asthma in a tertiary teaching
hospital in Bengaluru.
Materials and methods: 100 prescriptions from patients with established diagnosis of acute
exacerbation of bronchial asthma were assessed from the Department of Pulmonary Medicine
and the data gathered was analysed using MS Excel.
Results: Majority of the prescriptions irrespective of severity received inhalation b2 agonist
(formoterol) as a bronchodilator. Nebulization route was given for managing the acute exacerba-
tions followed by inhalation route. Hydrocortisone was prescribed to all patients for managing
acute exacerbations. Montelukast was used an adjuvant therapy. Most of them were prescribed
combination therapy. Doxophylline was prescribed among all the methylxanthines.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Drug utilization research is defined by WHO as ‘‘marketing,
distribution, prescription and use of drugs in a society, with
special emphasis on the resulting medical, social and economic
consequences”. Drug utilization evaluation (DUE) or drugutilization review (DUR) is an essential part of pharmaco-
epidemiological studies which provide a proper understanding
usage pattern of drugs, quality and efficiency use of drugs and
its outcomes. DUR can play a key role in helping the health-
care system to understand, interpret and improve the prescrib-
ing administration and to maintain the rational use of drugs
which assist the physician’s prescribing attitude in accordance
with the predetermined standards by allocating them with the
feed-back and also in designing, conducting and imparting
educational programmes for healthcare providers [1,2].rculosis.
Table 1 Demographic data.
Age (in years) Male Female Total (n= 100)
10–19 3 3 6
20–29 27 14 41
30–39 9 7 16
40–49 14 10 24
50–59 4 3 7
60–69 2 2 4
70–80 1 1 2
Table 2 Asthmatic medications.
Category Drugs
b agonists Salbutamol, formoterol
Corticosteroids Hydrocortisone, budesonide, methyl
prednisolone
Methylxanthines Etophylline, theophylline, doxophylline
Anticholinergics Ipratropium bromide
Leukotriene
modifiers
Montelukast
Anti histamines Levocetirizine, fexofenadine
Table 3 Prescribed asthmatic medications.
Drugs Number of prescriptions
N= 100
Salbutamol 7
Salbutamol + ipratropium bromide 87
Formoterol + budesonide 26
Etophylline + theophylline 34
Doxophylline 53
Budesonide 53
Hydrocortisone 61
Methyl prednisolone 7
Dexamethasone 1
Montelukast 57
Fexofenadine 2
Levocetirizine 3
20 B.T. Jayadeva, P. PanchaksharimathAsthma is a chronic inflammatory disorder of the airways
characterized by bronchial hyper-responsiveness and airflow
limitation that may vary in severity and frequency from per-
son to person. The symptoms of asthma include recurrent
episodes of wheezing, breathlessness, chest tightness and
cough [3]. The characteristic pathophysiological changes in
asthma involve several inflammatory cells and mediators
that contribute to symptoms. In India, asthma is known
to be one of the major causes of morbidity and mortality,
comprising about 3–11% of adults and 3–5% of paediatric
population [4]. The target of asthma treatment is to achieve
and maintain clinical control.
According to GINA (Global Initiative for Asthma) guideli-
nes, various drugs are suggested for the management of
asthma that includes long and short acting b2 agonists (salbu-
tamol, salmeterol, formoterol), corticosteroids (fluticasone,
prednisolone, budesonide), xanthine derivatives (theophylline)
and leukotriene receptor antagonists (Montelukast). These
drugs can be used alone or in conjunction with other antiasth-
matic drugs [5].The present study was done to describe trends
in the consumption of drugs for managing acute exacerbation
of bronchial asthma in adult population in a health-care
system.
Aim and objective
The aim was to evaluate drug utilization pattern in acute exac-
erbation of bronchial asthma among adult population at a
teaching tertiary-care hospital in Bengaluru.0
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Graph 1 Graphical presentation of demogMaterials and methods
A retrospective cross-sectional study analysing about 100 pre-
scriptions was carried out after taking approval from Institu-
tional Ethics Committee. Patients were selected on the basis
of inclusion and exclusion criteria. Patients of age more than
18 years diagnosed with acute exacerbation of bronchial
asthma were included and who were having other respiratory
problems like COPD, cardiac problems were excluded from
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Graph 2 Graphical presentation of prescribed asthmatic medications.
Drug utilization in patients with acute exacerbation of bronchial asthma 21Case records of the patients were assessed from the Depart-
ment of Pulmonary Medicine at Victoria Hospital attached to
Bangalore Medical College and Research Institute and the
data was collected. The data collection form provides the
information regarding the demographic details of the patient
which includes age, sex, occupation, past history, family
history and drug prescription which includes the drugs
prescribed, dosage form and frequency. The percentage of all
observed data was calculated.
Results
Demographic analysis of data revealed that there were 60%
men and 40% women in the study and also showed that
maximum asthmatic patients belonged to 20–29 years age
group (Table 1, Graph 1). The drugs prescribed primarily in
the study population are presented in Table 2. The results of
this study showed that most of the patients received combina-
tion therapy when compared with individual therapy. Majority
of the patients received combination therapy of b2 agonist and
corticosteroids via inhalational routes.
From Table 3 andGraph 2, the study showed salbutamol (b-
agonists) + ipratropium bromide (anti cholinergic) was the
most commonly used combination as bronchodilator in 87%
prescriptions followed by doxophylline (methyl xanthines) that
was used in 53% of prescriptions. Corticosteroids which were in
the form of hydrocortisone (61%), budesonide (53%), dexam-
ethasone (1%), and prednisolone (7%)were depicted in 100 pre-
scriptions. Majority of patients also received Montelukast,
leukotriene receptor antagonist (LTRA) as an adjuvant treat-
ment (57%) apart from b agonists and corticosteroids for the
control of asthmatic symptoms. Nebulization route was pre-
ferred for managing the acute exacerbations.Discussion
Prescription-based study evaluates the rationality of the pre-
scription. Guidelines for rational prescribing practices are put
forth to improve the standards of prescribing [6,7]. An interna-
tional body on asthma has enhanced the prescribing practice of
the physicians through various recommendations. In our studymajority of the prescriptions used nebulization as a preferred
route of drug delivery to manage acute exacerbations of asth-
matic episodes. Nebulizer produces an aerosol by blowing air
or oxygen through a solution to produce droplets requiring little
coordination from the patient as drug is inhaled through a face-
mask or a mouth piece using normal tidal breathing. Thus, it is
useful in patients who are unable to use conventional inhaler.
The disadvantages of using a nebulizer include the long time
commitmentmaintenance treatments and lack of portability [8].
However, the inhalation therapy through metered dose
inhalers was given to all patients who had treatment for acute
exacerbation of bronchial asthma at the time of discharge. The
inhalational route delivers more drugs locally and the dose
used is also less with less side effects. This is in accordance
to treatment guidelines, i.e. Inhalational therapy for asthma
to be the first choice [9,10]. The effectiveness of inhaler therapy
also depends on the inhaler technique. Patients may not be
adequately instructed in the inhaler technique, thereby reduc-
ing the amount of drug delivered to the lungs. Cochrane, in
a study stated it is important to reinforce the simple concept
that failure to instruct patients on how to use inhalers and to
reinforce these instructions will decrease compliance, whatever
the drug or inhalation device [11,1].
The most commonly prescribed inhaled bronchodilator was
salbutamol with ipratropium bromide (87%) followed by for-
moterol with budesonide (26%) which was in coherence with
the study done in Malaysia in which salbutamol was the most
commonly prescribed [11] and also study done in Bareilly, which
showed inhaled salbutamol was received by 100% of the
patients irrespective of the severity [12]. The study conducted
by Pinal et al. showed that 84% of patients [4] and 76% of
patients in Shimpi et al. [1] were given combination therapy over
monotherapy. The reason for using short acting b2 agonist i.e
salbutamol is due to its rapid onset and its low cost. In our study
injection hydrocortisone (61%) was also used in managing an
acute asthma attack. It prevents the side effect of inhaled medi-
cation which causes irritation on respiratory tract. NAEPP
guidelines recommend corticosteroids by oral route even for
severe exacerbation and it is reported to be as effective as intra-
venous route [13]. Anticholinergics were less prescribed as
monotherapy but was given in combination with, as they are
preferred medication for treating COPD instead of asthma.
22 B.T. Jayadeva, P. PanchaksharimathIntravenous doxophylline was the most commonly pre-
scribed methylxanthines. Doxophylline is preferred over theo-
phylline for it has less cardio-toxic effects than the former with
preserved muco-regulatory and anti-inflammatory properties.
Hence, doxophylline may constitute a safe and effective alter-
native treatment to aminophylline/theophylline in the treat-
ment of acute exacerbation of bronchial asthma [14].
However, Faiz et al. conclude that there is no significant differ-
ence in spirometric variables between doxophylline and theo-
phylline [15]. The conclusions of Faiz et al. are further
reinforced by the study of Margay et al. [16], but he concludes
that doxophylline has a better safety profile over theophylline.
Corticosteroids constituted the most commonly used medi-
cation and intravenous was the preferred route, and was pre-
scribed in 61% of the prescriptions, in contrast to study
done by Sayadeda et al., corticosteroid was given by IV route
in 100% cases of severe exacerbation and some cases of severe
exacerbation were also given MgSO4 (28.57%) for additional
bronchodilatation [12]. Montelukast, a leukotriene receptor
antagonist (57%) was seen in most of the prescription as
add-on therapy. It was prescribed as a fixed dose combination
with levocetirizine (36.8%) in a study done by Rajathilagam
et al. [17]. Limitations of our study were lack of follow up
and cost effectiveness which should have been done. For
higher authenticity more number of prescriptions should have
been included in our study.
Conclusion
b2 agonists Combinations and corticosteroids are themost com-
monly prescribed combination drugs for asthma followed by
methylxanthines. The most commonly prescribed asthmatic
medication in combination therapy was inhaled salbutamol
with ipratropium followed by intravenous hydrocortisone and
oral Montelukast. The most commonly prescribed methylxan-
thinewas intravenous doxophylline.Nebulizationwas preferred
route to tackle the acute exacerbation of asthmatic symptoms.
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